NautaDutilh, together with Weil, Gotshal & Manges, assisted global biopharmaceutical company Sanofi (listed on Euronext and NYSE) with its takeover of Belgian biotech company Ablynx (listed on Euronext Brussels and Nasdaq).
Sanofi will acquire all outstanding ordinary shares, including American depositary shares (ADS), warrants and convertible bonds of Ablynx at a cash price of €45 per share which represents an aggregate equity value of approximately €3.9 billion.
Sanofi has complied with the formalities set forth in the Belgian takeover legislation and filed the mandatory documents with the Belgian Financial Services and Markets Authority (FSMA). A notice was published by the FSMA on its website today. It is yet unclear when the acceptance period of the offer will start and when the transaction will close.
Ablynx's most advanced product in development is caplacizumab (anti-vWF Nanobody), for treatment of the life-threatening autoimmune blood disorder acquired thrombotic thrombocytopenic purpura (aTTP). This product will strengthen Sanofi's position in rare blood-disorder medications.
NautaDutilh's team was led by Elke Janssens and Dirk Van Gerven and was assisted by Michiel Nuitten, Louisa Vandepitte, Frederik Meuwissen, Christel Brion, Philippe François, Anneleen Abbeel, Ken Lioen, Nathalie Van Landuyt, Stefanie Hardy, Yolanda Hebbrecht, Roeland Van Cleemput, Lentle Nijs, and Aurelie Pollie.
Sanofi has issued an official press release which can be viewed here.